Immune Response to Glycated and Oxidized LDL in IDDM Patients With and Without Renal Disease
暂无分享,去创建一个
[1] L. Niskanen,et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[2] M. Taskinen,et al. Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease , 1996, Diabetes.
[3] G. Bellomo,et al. Autoantibodies Against Oxidatively Modified Low-Density Lipoproteins in NIDDM , 1995, Diabetes.
[4] L. Tenkanen,et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. , 1994, Archives of internal medicine.
[5] M. Kendall,et al. The oxidation hypothesis of atherosclerosis , 1994, The Lancet.
[6] A. Bowie,et al. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? , 1993, Atherosclerosis.
[7] M. Brownlee,et al. Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.
[8] J. Salonen,et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.
[9] D. Sullivan,et al. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. , 1992, Biochemical pharmacology.
[10] J L Witztum,et al. Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[11] J L Witztum,et al. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.